Neuroview Technology

NEUROVIEW TECHNOLOGY'S breakthrough device is a small implantable subcutaneous long-term brain monitor using EEG. There are no long-term electroencephalography (EEG) monitor devices approved by the FDA. All EEG studies even if intensive are limited to no more than a few days providing very little information. However, all brain disorders are dynamic in nature changing over time. EEG has been in clinical use for many decades and has been utilized in vascular disease, Parkinson's, psychiatric disorders, and mainly epilepsy. Epilepsy affects almost 4 million adults and children in United States with up to 30% who do not effectively respond to medical therapy. To date, no reliable objective biometric measure for epilepsy and seizures exists. Physicians rely on subjective seizure reporting by patients and families which is 40-50% accurate. NEUROVIEW'S novel technology accurately identifies unrecognized seizures, prevents false characterization of events, and provides information to optimize management. Under treated or untreated seizures resulting from lack of accurate seizure recognition is associated with a poor quality of life, increases the risk of accidents and sudden death, and greatly contributes to the already high cost of epilepsy. This technology is the first long-term, minimally invasive device for EEG monitoring. Data-driven decision-making (DDDM): data science, data analysis and intelligent programming are essential to achieve success in healthcare by democratizing and personalizing healthcare. Employing AI/ML/DDN to analyze long-term EEG data will create a comprehensive knowledge platform that is updated continuously with ongoing information and from other separate knowledge domains for personalized and group utilization by all stake holders. Improving outcomes, reducing costs, reducing time to optimum treatments, improving diagnostics, predicting outcomes, etc., is some of the anticipated personalized care that AI will bring to brain disorders.

• Employees 2
• Founded 2017
• Total Funding $554491